Skip to content

MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes

Early Detection of Mild Cognitive Impairment in Young Diabetes Patients Using the MoCa Test

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02545062
Enrollment
170
Registered
2015-09-09
Start date
2014-05-31
Completion date
2016-08-31
Last updated
2015-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus Type 1, Diabetes Mellitus Type 2, Mild Cognitive Impairment

Brief summary

T2D and cognitive impairment are two of the most common chronic condition found in persons 60 years and older. Diabetes type 2 increases with age and studies suggest that the diabetes is one of the risk factor for cognitive impairment and dementia. Although there is much recent research showing that diabetics at every age have more cognitive impairment and dementia than non-diabetics, relatively little attention has been paid to the implications of this complication in the management of T2D in terms of screening, prevention, education and treatment adherence. There are now guidelines for periodic evaluation of patients with diabetes as early detection of complications of the disease, but so far there are no similar assessment and monitoring of cognitive function. In this study the investigators examine cognitive function in young diabetic patients (from 20 to 55) using the MoCa test, that allows detection of mild cognitive impairment, and may be carried out during a visit, an annual advisory diabetes clinic.

Detailed description

1. Patients on a routine visit to the diabetes clinic, who meet the inclusion criteria, will be recruited for the test. They will be given an explanation of the study and the questionnaire by the principal investigator. 2. Sign a consent form. 3. Performance and execution of MOCA test: * Fingerstick blood glucose for pre-cognitive testing performed (to avoid testing any participant with a serum glucose \< 70 mg/dl); * In the presence of hypoglycemia, the participant should be given a snack and begin the test only after the glucose level rises. Alternatively delay executing the Test 4. Details from the patient's file are registered, such as: duration of the disease, family history, presence of macro and micro vascular complications, lifestyle, years of education, and the results of relevant laboratory accuracy. 5. For each patient a medical file is opened containing the initials and serial number of his research. All results are then encoded and analyzed anonymously

Interventions

The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.

Sponsors

Clalit Health Services
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* type 1 and 2 diabetes meIlitus * 20 to 55 years old * up to 15 years of diabetes disease duration * fluent speech and read hebrew's language only

Exclusion criteria

* not meeting the inclusion criteria * psychiatric disease * dementia * chronic use of alcohol or illegal drugs * use of medication that can alter the attention or cognition of the participant * active cardiovascular disease in the previous six months before the investigation * oncology disease in the previous six months before the investigation

Design outcomes

Primary

MeasureTime frame
The differences between the MoCa test score in diabetics and in a control group of non diabetics1 year

Secondary

MeasureTime frame
The relation between the MoCa test score and glycemic control, in terms of HA1C value, in the past year before recruitment1 year
The relation between the MoCa test score and the presence of microvascular complications, retinopathy, polyneuropathy and nephropathy1 year
The relation between the MoCa test score and the presence of macrovascular complication, ischemic heart disease, non-fatal myocardial infarct, stable and unstable angina, heart failure, non-fatal stroke, peripheral vascular disease1year

Countries

Israel

Contacts

Primary ContactViviana VO Ostrovsky, MD
vivianaos@clalit.org.il+972504402029

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026